Home

PBYI

Puma Biotechnology Inc

NASDAQHealthcareBiotechnology

$7.49

+3.17%

2026-05-08

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Key Fundamentals

P/E Ratio

12.49

Forward P/E

11.72

EPS (TTM)

$0.61

ROE

28.0%

Revenue Growth (YoY)

27.7%

Profit Margin

13.6%

Debt/Equity

21.90

Price/Book

2.95

Beta

1.23

Market Cap

$387.8M

Avg Volume (10D)

276K

Recent Breakout Signals

No recent breakout signals detected for PBYI.

Recent Price Range (60 Days)

60D High

$7.90

60D Low

$5.50

Avg Volume

347K

Latest Close

$7.49

Get breakout alerts for PBYI

Sign up for Breakout Scanner to receive daily notifications when PBYI triggers breakout signals. Build custom AI screeners and backtest strategies.

Start Free Trial

7-day free trial. No card required.

Puma Biotechnology Inc (PBYI) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors PBYI daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. PBYI operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.